Login / Signup

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.

Yang MengNadine HertelJohn EllisEdith MoraisHelen JohnsonZoe PhilipsNeil RoskellAndrew WalkerDawn Lee
Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2018)
Nivolumab is a cost-effective treatment for advanced melanoma patients in England.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • combination therapy
  • clinical trial
  • open label